nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—ABCB1—esophageal cancer	0.701	1	CbGaD
Rivaroxaban—Wound secretion—Capecitabine—esophageal cancer	0.00839	0.0739	CcSEcCtD
Rivaroxaban—Hemiparesis—Methotrexate—esophageal cancer	0.00433	0.0381	CcSEcCtD
Rivaroxaban—Amylase increased—Cisplatin—esophageal cancer	0.00347	0.0305	CcSEcCtD
Rivaroxaban—Infection—Carboplatin—esophageal cancer	0.002	0.0176	CcSEcCtD
Rivaroxaban—Haematoma—Capecitabine—esophageal cancer	0.00194	0.0171	CcSEcCtD
Rivaroxaban—Pain—Carboplatin—esophageal cancer	0.00172	0.0151	CcSEcCtD
Rivaroxaban—Blister—Capecitabine—esophageal cancer	0.00169	0.0149	CcSEcCtD
Rivaroxaban—Haemoptysis—Capecitabine—esophageal cancer	0.00165	0.0145	CcSEcCtD
Rivaroxaban—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00151	0.0133	CcSEcCtD
Rivaroxaban—Contusion—Capecitabine—esophageal cancer	0.0014	0.0123	CcSEcCtD
Rivaroxaban—Rectal haemorrhage—Capecitabine—esophageal cancer	0.00135	0.0119	CcSEcCtD
Rivaroxaban—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00134	0.0118	CcSEcCtD
Rivaroxaban—Renal failure acute—Cisplatin—esophageal cancer	0.0013	0.0114	CcSEcCtD
Rivaroxaban—Blood bilirubin increased—Capecitabine—esophageal cancer	0.00129	0.0113	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.0012	0.0106	CcSEcCtD
Rivaroxaban—Blood creatinine increased—Cisplatin—esophageal cancer	0.00112	0.00989	CcSEcCtD
Rivaroxaban—Ecchymosis—Capecitabine—esophageal cancer	0.0011	0.00969	CcSEcCtD
Rivaroxaban—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00101	0.0089	CcSEcCtD
Rivaroxaban—Swelling—Capecitabine—esophageal cancer	0.001	0.00882	CcSEcCtD
Rivaroxaban—Renal failure acute—Capecitabine—esophageal cancer	0.000957	0.00843	CcSEcCtD
Rivaroxaban—Dermatitis bullous—Capecitabine—esophageal cancer	0.000925	0.00814	CcSEcCtD
Rivaroxaban—Renal failure—Cisplatin—esophageal cancer	0.000908	0.008	CcSEcCtD
Rivaroxaban—Pain in extremity—Capecitabine—esophageal cancer	0.000884	0.00778	CcSEcCtD
Rivaroxaban—Osteoarthritis—Capecitabine—esophageal cancer	0.000884	0.00778	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000884	0.00778	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000874	0.00769	CcSEcCtD
Rivaroxaban—Blood creatinine increased—Capecitabine—esophageal cancer	0.000828	0.00729	CcSEcCtD
Rivaroxaban—Ecchymosis—Methotrexate—esophageal cancer	0.00082	0.00721	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Cisplatin—esophageal cancer	0.000819	0.00721	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Cisplatin—esophageal cancer	0.000815	0.00718	CcSEcCtD
Rivaroxaban—Urethral disorder—Cisplatin—esophageal cancer	0.000813	0.00716	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Capecitabine—esophageal cancer	0.000807	0.00711	CcSEcCtD
Rivaroxaban—Eye disorder—Cisplatin—esophageal cancer	0.000775	0.00682	CcSEcCtD
Rivaroxaban—Cardiac disorder—Cisplatin—esophageal cancer	0.00077	0.00678	CcSEcCtD
Rivaroxaban—Immune system disorder—Cisplatin—esophageal cancer	0.000749	0.0066	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Cisplatin—esophageal cancer	0.000748	0.00658	CcSEcCtD
Rivaroxaban—Angina pectoris—Capecitabine—esophageal cancer	0.000744	0.00655	CcSEcCtD
Rivaroxaban—Renal failure acute—Methotrexate—esophageal cancer	0.000713	0.00627	CcSEcCtD
Rivaroxaban—Muscle spasms—Cisplatin—esophageal cancer	0.000694	0.00611	CcSEcCtD
Rivaroxaban—Infestation NOS—Capecitabine—esophageal cancer	0.000681	0.006	CcSEcCtD
Rivaroxaban—Infestation—Capecitabine—esophageal cancer	0.000681	0.006	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000675	0.00594	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Cisplatin—esophageal cancer	0.00067	0.0059	CcSEcCtD
Rivaroxaban—Renal failure—Capecitabine—esophageal cancer	0.00067	0.00589	CcSEcCtD
Rivaroxaban—Anaemia—Cisplatin—esophageal cancer	0.000667	0.00588	CcSEcCtD
Rivaroxaban—Jaundice—Capecitabine—esophageal cancer	0.000664	0.00584	CcSEcCtD
Rivaroxaban—Urinary tract infection—Capecitabine—esophageal cancer	0.000662	0.00583	CcSEcCtD
Rivaroxaban—Osteoarthritis—Methotrexate—esophageal cancer	0.000658	0.00579	CcSEcCtD
Rivaroxaban—Malaise—Cisplatin—esophageal cancer	0.000651	0.00573	CcSEcCtD
Rivaroxaban—Haematuria—Capecitabine—esophageal cancer	0.000649	0.00572	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000644	0.00567	CcSEcCtD
Rivaroxaban—Epistaxis—Capecitabine—esophageal cancer	0.000642	0.00566	CcSEcCtD
Rivaroxaban—Agranulocytosis—Capecitabine—esophageal cancer	0.000636	0.0056	CcSEcCtD
Rivaroxaban—Haemoglobin—Capecitabine—esophageal cancer	0.000615	0.00541	CcSEcCtD
Rivaroxaban—Haemorrhage—Capecitabine—esophageal cancer	0.000611	0.00538	CcSEcCtD
Rivaroxaban—Hepatitis—Capecitabine—esophageal cancer	0.000611	0.00538	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000611	0.00537	CcSEcCtD
Rivaroxaban—Discomfort—Cisplatin—esophageal cancer	0.000607	0.00535	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Capecitabine—esophageal cancer	0.000604	0.00532	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Capecitabine—esophageal cancer	0.000601	0.00529	CcSEcCtD
Rivaroxaban—Urethral disorder—Capecitabine—esophageal cancer	0.000599	0.00528	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Cisplatin—esophageal cancer	0.000589	0.00519	CcSEcCtD
Rivaroxaban—Oedema—Cisplatin—esophageal cancer	0.000589	0.00519	CcSEcCtD
Rivaroxaban—Infection—Cisplatin—esophageal cancer	0.000585	0.00515	CcSEcCtD
Rivaroxaban—Erythema multiforme—Capecitabine—esophageal cancer	0.000578	0.00509	CcSEcCtD
Rivaroxaban—Nervous system disorder—Cisplatin—esophageal cancer	0.000578	0.00509	CcSEcCtD
Rivaroxaban—Tachycardia—Cisplatin—esophageal cancer	0.000575	0.00506	CcSEcCtD
Rivaroxaban—Skin disorder—Cisplatin—esophageal cancer	0.000572	0.00504	CcSEcCtD
Rivaroxaban—Eye disorder—Capecitabine—esophageal cancer	0.000571	0.00503	CcSEcCtD
Rivaroxaban—Cardiac disorder—Capecitabine—esophageal cancer	0.000567	0.005	CcSEcCtD
Rivaroxaban—Angiopathy—Capecitabine—esophageal cancer	0.000555	0.00488	CcSEcCtD
Rivaroxaban—Immune system disorder—Capecitabine—esophageal cancer	0.000552	0.00486	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Capecitabine—esophageal cancer	0.000551	0.00485	CcSEcCtD
Rivaroxaban—Hypotension—Cisplatin—esophageal cancer	0.000551	0.00485	CcSEcCtD
Rivaroxaban—Dyspnoea—Cisplatin—esophageal cancer	0.000525	0.00463	CcSEcCtD
Rivaroxaban—Back pain—Capecitabine—esophageal cancer	0.000515	0.00453	CcSEcCtD
Rivaroxaban—Muscle spasms—Capecitabine—esophageal cancer	0.000512	0.00451	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000509	0.00448	CcSEcCtD
Rivaroxaban—Infestation NOS—Methotrexate—esophageal cancer	0.000507	0.00446	CcSEcCtD
Rivaroxaban—Infestation—Methotrexate—esophageal cancer	0.000507	0.00446	CcSEcCtD
Rivaroxaban—Pain—Cisplatin—esophageal cancer	0.000504	0.00444	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000503	0.00443	CcSEcCtD
Rivaroxaban—F10—Hemostasis—CFL1—esophageal cancer	0.000501	0.0027	CbGpPWpGaD
Rivaroxaban—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.0005	0.00269	CbGpPWpGaD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.0005	0.00269	CbGpPWpGaD
Rivaroxaban—Renal failure—Methotrexate—esophageal cancer	0.000498	0.00439	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Capecitabine—esophageal cancer	0.000494	0.00435	CcSEcCtD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000493	0.00265	CbGpPWpGaD
Rivaroxaban—Anaemia—Capecitabine—esophageal cancer	0.000492	0.00433	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—ST6GAL1—esophageal cancer	0.000487	0.00262	CbGpPWpGaD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000486	0.00262	CbGpPWpGaD
Rivaroxaban—Feeling abnormal—Cisplatin—esophageal cancer	0.000486	0.00428	CcSEcCtD
Rivaroxaban—Haematuria—Methotrexate—esophageal cancer	0.000483	0.00426	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—ADH7—esophageal cancer	0.000482	0.00259	CbGpPWpGaD
Rivaroxaban—Malaise—Capecitabine—esophageal cancer	0.00048	0.00423	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00048	0.00422	CcSEcCtD
Rivaroxaban—Epistaxis—Methotrexate—esophageal cancer	0.000478	0.00421	CcSEcCtD
Rivaroxaban—Syncope—Capecitabine—esophageal cancer	0.000477	0.0042	CcSEcCtD
Rivaroxaban—Agranulocytosis—Methotrexate—esophageal cancer	0.000473	0.00417	CcSEcCtD
Rivaroxaban—F10—Hemostasis—GNG7—esophageal cancer	0.000472	0.00254	CbGpPWpGaD
Rivaroxaban—Loss of consciousness—Capecitabine—esophageal cancer	0.000468	0.00412	CcSEcCtD
Rivaroxaban—Haemoglobin—Methotrexate—esophageal cancer	0.000458	0.00403	CcSEcCtD
Rivaroxaban—Haemorrhage—Methotrexate—esophageal cancer	0.000455	0.00401	CcSEcCtD
Rivaroxaban—Hepatitis—Methotrexate—esophageal cancer	0.000455	0.00401	CcSEcCtD
Rivaroxaban—Chest pain—Capecitabine—esophageal cancer	0.000453	0.00399	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00045	0.00396	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Methotrexate—esophageal cancer	0.00045	0.00396	CcSEcCtD
Rivaroxaban—Discomfort—Capecitabine—esophageal cancer	0.000448	0.00394	CcSEcCtD
Rivaroxaban—Urethral disorder—Methotrexate—esophageal cancer	0.000446	0.00393	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000445	0.0024	CbGpPWpGaD
Rivaroxaban—Dry mouth—Capecitabine—esophageal cancer	0.000443	0.0039	CcSEcCtD
Rivaroxaban—Oedema—Capecitabine—esophageal cancer	0.000434	0.00382	CcSEcCtD
Rivaroxaban—Hypersensitivity—Cisplatin—esophageal cancer	0.000434	0.00382	CcSEcCtD
Rivaroxaban—Infection—Capecitabine—esophageal cancer	0.000432	0.0038	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—ENO1—esophageal cancer	0.000431	0.00232	CbGpPWpGaD
Rivaroxaban—Erythema multiforme—Methotrexate—esophageal cancer	0.00043	0.00379	CcSEcCtD
Rivaroxaban—Shock—Capecitabine—esophageal cancer	0.000427	0.00376	CcSEcCtD
Rivaroxaban—Nervous system disorder—Capecitabine—esophageal cancer	0.000426	0.00375	CcSEcCtD
Rivaroxaban—Eye disorder—Methotrexate—esophageal cancer	0.000425	0.00374	CcSEcCtD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000425	0.00229	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000424	0.00228	CbGpPWpGaD
Rivaroxaban—Tachycardia—Capecitabine—esophageal cancer	0.000424	0.00373	CcSEcCtD
Rivaroxaban—Asthenia—Cisplatin—esophageal cancer	0.000423	0.00372	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—ADH1B—esophageal cancer	0.000423	0.00228	CbGpPWpGaD
Rivaroxaban—Cardiac disorder—Methotrexate—esophageal cancer	0.000422	0.00372	CcSEcCtD
Rivaroxaban—Skin disorder—Capecitabine—esophageal cancer	0.000422	0.00371	CcSEcCtD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000422	0.00227	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000419	0.00225	CbGpPWpGaD
Rivaroxaban—Angiopathy—Methotrexate—esophageal cancer	0.000413	0.00364	CcSEcCtD
Rivaroxaban—Immune system disorder—Methotrexate—esophageal cancer	0.000411	0.00362	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Methotrexate—esophageal cancer	0.00041	0.00361	CcSEcCtD
Rivaroxaban—Hypotension—Capecitabine—esophageal cancer	0.000406	0.00357	CcSEcCtD
Rivaroxaban—Diarrhoea—Cisplatin—esophageal cancer	0.000403	0.00355	CcSEcCtD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.0004	0.00215	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.000398	0.00214	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—BLVRB—esophageal cancer	0.000396	0.00213	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—SLC52A3—esophageal cancer	0.000396	0.00213	CbGpPWpGaD
Rivaroxaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—esophageal cancer	0.000395	0.00213	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP26A1—esophageal cancer	0.000393	0.00212	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000388	0.00209	CbGpPWpGaD
Rivaroxaban—Dyspnoea—Capecitabine—esophageal cancer	0.000387	0.00341	CcSEcCtD
Rivaroxaban—F10—Hemostasis—HSPA5—esophageal cancer	0.000385	0.00207	CbGpPWpGaD
Rivaroxaban—Back pain—Methotrexate—esophageal cancer	0.000383	0.00337	CcSEcCtD
Rivaroxaban—Dyspepsia—Capecitabine—esophageal cancer	0.000382	0.00337	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000375	0.0033	CcSEcCtD
Rivaroxaban—Vomiting—Cisplatin—esophageal cancer	0.000375	0.0033	CcSEcCtD
Rivaroxaban—Fatigue—Capecitabine—esophageal cancer	0.000375	0.0033	CcSEcCtD
Rivaroxaban—Rash—Cisplatin—esophageal cancer	0.000372	0.00327	CcSEcCtD
Rivaroxaban—Constipation—Capecitabine—esophageal cancer	0.000371	0.00327	CcSEcCtD
Rivaroxaban—Pain—Capecitabine—esophageal cancer	0.000371	0.00327	CcSEcCtD
Rivaroxaban—Dermatitis—Cisplatin—esophageal cancer	0.000371	0.00327	CcSEcCtD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00037	0.00199	CbGpPWpGaD
Rivaroxaban—Ill-defined disorder—Methotrexate—esophageal cancer	0.000368	0.00324	CcSEcCtD
Rivaroxaban—Anaemia—Methotrexate—esophageal cancer	0.000366	0.00322	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—GSTO1—esophageal cancer	0.000365	0.00197	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSTO1—esophageal cancer	0.00036	0.00194	CbGpPWpGaD
Rivaroxaban—Feeling abnormal—Capecitabine—esophageal cancer	0.000358	0.00315	CcSEcCtD
Rivaroxaban—Malaise—Methotrexate—esophageal cancer	0.000357	0.00315	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000355	0.00313	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000354	0.0019	CbGpPWpGaD
Rivaroxaban—Nausea—Cisplatin—esophageal cancer	0.00035	0.00308	CcSEcCtD
Rivaroxaban—Urticaria—Capecitabine—esophageal cancer	0.000345	0.00304	CcSEcCtD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000344	0.00185	CbGpPWpGaD
Rivaroxaban—Abdominal pain—Capecitabine—esophageal cancer	0.000343	0.00302	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000342	0.00184	CbGpPWpGaD
Rivaroxaban—Chest pain—Methotrexate—esophageal cancer	0.000337	0.00297	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—SLC10A2—esophageal cancer	0.000336	0.00181	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CA1—esophageal cancer	0.000336	0.00181	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—ACTB—esophageal cancer	0.000335	0.0018	CbGpPWpGaD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000335	0.00295	CcSEcCtD
Rivaroxaban—Discomfort—Methotrexate—esophageal cancer	0.000333	0.00293	CcSEcCtD
Rivaroxaban—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000332	0.00179	CbGpPWpGaD
Rivaroxaban—Anaphylactic shock—Methotrexate—esophageal cancer	0.000323	0.00285	CcSEcCtD
Rivaroxaban—Infection—Methotrexate—esophageal cancer	0.000321	0.00283	CcSEcCtD
Rivaroxaban—Hypersensitivity—Capecitabine—esophageal cancer	0.00032	0.00282	CcSEcCtD
Rivaroxaban—Nervous system disorder—Methotrexate—esophageal cancer	0.000317	0.00279	CcSEcCtD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000316	0.0017	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—HMOX1—esophageal cancer	0.000314	0.00169	CbGpPWpGaD
Rivaroxaban—Skin disorder—Methotrexate—esophageal cancer	0.000314	0.00277	CcSEcCtD
Rivaroxaban—Asthenia—Capecitabine—esophageal cancer	0.000312	0.00274	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—CA2—esophageal cancer	0.000308	0.00166	CbGpPWpGaD
Rivaroxaban—Pruritus—Capecitabine—esophageal cancer	0.000307	0.00271	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—HSPA5—esophageal cancer	0.000303	0.00163	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000302	0.00163	CbGpPWpGaD
Rivaroxaban—Hypotension—Methotrexate—esophageal cancer	0.000302	0.00266	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—SMAD4—esophageal cancer	0.000302	0.00162	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000301	0.00162	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000301	0.00162	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000298	0.00161	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—ALDH2—esophageal cancer	0.000298	0.0016	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Capecitabine—esophageal cancer	0.000297	0.00262	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—CALR—esophageal cancer	0.000294	0.00158	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—GHRL—esophageal cancer	0.000289	0.00155	CbGpPWpGaD
Rivaroxaban—Dyspnoea—Methotrexate—esophageal cancer	0.000288	0.00254	CcSEcCtD
Rivaroxaban—Dizziness—Capecitabine—esophageal cancer	0.000287	0.00253	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—ADH7—esophageal cancer	0.000286	0.00154	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PLCE1—esophageal cancer	0.000286	0.00154	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—ABL1—esophageal cancer	0.000285	0.00154	CbGpPWpGaD
Rivaroxaban—Dyspepsia—Methotrexate—esophageal cancer	0.000285	0.00251	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—FBXW7—esophageal cancer	0.000284	0.00153	CbGpPWpGaD
Rivaroxaban—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000283	0.00153	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GSTT1—esophageal cancer	0.000283	0.00152	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000283	0.00152	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP2A6—esophageal cancer	0.00028	0.00151	CbGpPWpGaD
Rivaroxaban—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000279	0.00246	CcSEcCtD
Rivaroxaban—Fatigue—Methotrexate—esophageal cancer	0.000279	0.00245	CcSEcCtD
Rivaroxaban—Pain—Methotrexate—esophageal cancer	0.000277	0.00243	CcSEcCtD
Rivaroxaban—Vomiting—Capecitabine—esophageal cancer	0.000276	0.00243	CcSEcCtD
Rivaroxaban—Rash—Capecitabine—esophageal cancer	0.000274	0.00241	CcSEcCtD
Rivaroxaban—Dermatitis—Capecitabine—esophageal cancer	0.000274	0.00241	CcSEcCtD
Rivaroxaban—Headache—Capecitabine—esophageal cancer	0.000272	0.0024	CcSEcCtD
Rivaroxaban—Feeling abnormal—Methotrexate—esophageal cancer	0.000266	0.00235	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000266	0.00143	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—PTGS1—esophageal cancer	0.000265	0.00143	CbGpPWpGaD
Rivaroxaban—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000264	0.00233	CcSEcCtD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000261	0.0014	CbGpPWpGaD
Rivaroxaban—Nausea—Capecitabine—esophageal cancer	0.000258	0.00227	CcSEcCtD
Rivaroxaban—Urticaria—Methotrexate—esophageal cancer	0.000257	0.00226	CcSEcCtD
Rivaroxaban—Abdominal pain—Methotrexate—esophageal cancer	0.000256	0.00225	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—ADH1B—esophageal cancer	0.000251	0.00135	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—HIF1A—esophageal cancer	0.000247	0.00133	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000245	0.00132	CbGpPWpGaD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000244	0.00131	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00024	0.00129	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—TYMP—esophageal cancer	0.00024	0.00129	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Methotrexate—esophageal cancer	0.000238	0.0021	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—CYP26A1—esophageal cancer	0.000233	0.00126	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000232	0.00125	CbGpPWpGaD
Rivaroxaban—Asthenia—Methotrexate—esophageal cancer	0.000232	0.00204	CcSEcCtD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000229	0.00123	CbGpPWpGaD
Rivaroxaban—Pruritus—Methotrexate—esophageal cancer	0.000229	0.00201	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—ALOX15—esophageal cancer	0.000227	0.00122	CbGpPWpGaD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000226	0.00122	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—CYP1B1—esophageal cancer	0.000226	0.00121	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	0.000225	0.00121	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000224	0.00121	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000223	0.0012	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Methotrexate—esophageal cancer	0.000221	0.00195	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—GSTO1—esophageal cancer	0.000217	0.00117	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—TPI1—esophageal cancer	0.000217	0.00117	CbGpPWpGaD
Rivaroxaban—Dizziness—Methotrexate—esophageal cancer	0.000214	0.00188	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—CYP19A1—esophageal cancer	0.000212	0.00114	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000209	0.00113	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ALDOB—esophageal cancer	0.000208	0.00112	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—NOS2—esophageal cancer	0.000206	0.00111	CbGpPWpGaD
Rivaroxaban—Vomiting—Methotrexate—esophageal cancer	0.000206	0.00181	CcSEcCtD
Rivaroxaban—Rash—Methotrexate—esophageal cancer	0.000204	0.0018	CcSEcCtD
Rivaroxaban—Dermatitis—Methotrexate—esophageal cancer	0.000204	0.00179	CcSEcCtD
Rivaroxaban—Headache—Methotrexate—esophageal cancer	0.000203	0.00178	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	0.000202	0.00109	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GAPDH—esophageal cancer	0.0002	0.00108	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CRABP1—esophageal cancer	0.000198	0.00107	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000198	0.00106	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000197	0.00106	CbGpPWpGaD
Rivaroxaban—Nausea—Methotrexate—esophageal cancer	0.000192	0.00169	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—GNG7—esophageal cancer	0.000189	0.00102	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000186	0.001	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—CREBBP—esophageal cancer	0.000185	0.000994	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000183	0.000983	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000181	0.000972	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00018	0.00097	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ALDH2—esophageal cancer	0.000177	0.000951	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—CASP8—esophageal cancer	0.000175	0.000944	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.00017	0.000914	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTT1—esophageal cancer	0.000168	0.000905	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000168	0.000902	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP2A6—esophageal cancer	0.000166	0.000894	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000166	0.000891	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—NOS3—esophageal cancer	0.000165	0.00089	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000165	0.000889	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTGS1—esophageal cancer	0.000158	0.000848	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ENO1—esophageal cancer	0.000158	0.000848	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000157	0.000846	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000156	0.000841	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PSME2—esophageal cancer	0.000155	0.000835	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PSME1—esophageal cancer	0.000155	0.000835	CbGpPWpGaD
Rivaroxaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	0.000152	0.000818	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000147	0.000791	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000139	0.000749	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000138	0.000745	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	0.000137	0.000739	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000136	0.00073	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP1B1—esophageal cancer	0.000134	0.000721	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000133	0.000717	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000133	0.000715	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000132	0.000709	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.00013	0.000701	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000129	0.000694	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000127	0.000685	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000127	0.000685	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP19A1—esophageal cancer	0.000126	0.000678	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—EP300—esophageal cancer	0.000126	0.000677	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000123	0.000664	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000122	0.000657	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—HMOX1—esophageal cancer	0.000115	0.000618	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SLC52A3—esophageal cancer	0.000114	0.000614	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—BLVRB—esophageal cancer	0.000114	0.000614	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000113	0.000607	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ABCB1—esophageal cancer	0.00011	0.000594	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000105	0.000565	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000103	0.000557	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	9.87e-05	0.000531	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	9.73e-05	0.000524	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SLC10A2—esophageal cancer	9.7e-05	0.000522	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CA1—esophageal cancer	9.7e-05	0.000522	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	9.65e-05	0.000519	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PIK3CA—esophageal cancer	9.3e-05	0.000501	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TP53—esophageal cancer	9e-05	0.000484	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CA2—esophageal cancer	8.87e-05	0.000477	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	8.76e-05	0.000471	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	8.66e-05	0.000466	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	8.62e-05	0.000464	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SLC52A3—esophageal cancer	8.6e-05	0.000463	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—BLVRB—esophageal cancer	8.6e-05	0.000463	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8.34e-05	0.000449	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PLCE1—esophageal cancer	8.24e-05	0.000444	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ADH7—esophageal cancer	8.24e-05	0.000444	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	7.43e-05	0.0004	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CREBBP—esophageal cancer	7.37e-05	0.000397	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CA1—esophageal cancer	7.32e-05	0.000394	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SLC10A2—esophageal cancer	7.32e-05	0.000394	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ADH1B—esophageal cancer	7.23e-05	0.000389	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	7.22e-05	0.000389	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	7.06e-05	0.00038	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—TYMP—esophageal cancer	6.91e-05	0.000372	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP26A1—esophageal cancer	6.72e-05	0.000362	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CA2—esophageal cancer	6.69e-05	0.00036	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—NOS3—esophageal cancer	6.6e-05	0.000355	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ALOX15—esophageal cancer	6.55e-05	0.000353	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	6.38e-05	0.000343	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—TPI1—esophageal cancer	6.25e-05	0.000336	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTO1—esophageal cancer	6.25e-05	0.000336	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PLCE1—esophageal cancer	6.22e-05	0.000335	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ADH7—esophageal cancer	6.22e-05	0.000335	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	6.17e-05	0.000332	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTGS2—esophageal cancer	6.04e-05	0.000325	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ALDOB—esophageal cancer	5.99e-05	0.000322	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	5.87e-05	0.000316	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GAPDH—esophageal cancer	5.77e-05	0.00031	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CRABP1—esophageal cancer	5.71e-05	0.000308	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ADH1B—esophageal cancer	5.46e-05	0.000294	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GNG7—esophageal cancer	5.44e-05	0.000293	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	5.34e-05	0.000287	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SLC52A3—esophageal cancer	5.3e-05	0.000285	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—BLVRB—esophageal cancer	5.3e-05	0.000285	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—TYMP—esophageal cancer	5.21e-05	0.000281	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	5.12e-05	0.000275	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ALDH2—esophageal cancer	5.09e-05	0.000274	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP26A1—esophageal cancer	5.07e-05	0.000273	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—EP300—esophageal cancer	5.02e-05	0.00027	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	5e-05	0.000269	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ALOX15—esophageal cancer	4.94e-05	0.000266	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTT1—esophageal cancer	4.84e-05	0.000261	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP2A6—esophageal cancer	4.79e-05	0.000258	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTO1—esophageal cancer	4.71e-05	0.000254	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—TPI1—esophageal cancer	4.71e-05	0.000254	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTGS1—esophageal cancer	4.54e-05	0.000244	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ENO1—esophageal cancer	4.54e-05	0.000244	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ALDOB—esophageal cancer	4.52e-05	0.000243	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SLC10A2—esophageal cancer	4.51e-05	0.000243	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CA1—esophageal cancer	4.51e-05	0.000243	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PSME2—esophageal cancer	4.47e-05	0.000241	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PSME1—esophageal cancer	4.47e-05	0.000241	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GAPDH—esophageal cancer	4.35e-05	0.000234	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	4.34e-05	0.000234	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CRABP1—esophageal cancer	4.31e-05	0.000232	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	4.2e-05	0.000226	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CA2—esophageal cancer	4.12e-05	0.000222	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GNG7—esophageal cancer	4.1e-05	0.000221	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP1B1—esophageal cancer	3.86e-05	0.000208	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ALDH2—esophageal cancer	3.84e-05	0.000207	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PLCE1—esophageal cancer	3.83e-05	0.000206	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ADH7—esophageal cancer	3.83e-05	0.000206	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PIK3CA—esophageal cancer	3.71e-05	0.0002	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTT1—esophageal cancer	3.66e-05	0.000197	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP19A1—esophageal cancer	3.63e-05	0.000195	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP2A6—esophageal cancer	3.61e-05	0.000195	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ENO1—esophageal cancer	3.43e-05	0.000184	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTGS1—esophageal cancer	3.43e-05	0.000184	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	3.42e-05	0.000184	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PSME1—esophageal cancer	3.38e-05	0.000182	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PSME2—esophageal cancer	3.38e-05	0.000182	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ADH1B—esophageal cancer	3.36e-05	0.000181	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—HMOX1—esophageal cancer	3.31e-05	0.000178	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TYMP—esophageal cancer	3.21e-05	0.000173	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ABCB1—esophageal cancer	3.18e-05	0.000171	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP26A1—esophageal cancer	3.12e-05	0.000168	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ALOX15—esophageal cancer	3.04e-05	0.000164	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.91e-05	0.000157	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—TPI1—esophageal cancer	2.9e-05	0.000156	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.9e-05	0.000156	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.78e-05	0.00015	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.74e-05	0.000147	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.68e-05	0.000144	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.66e-05	0.000143	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GNG7—esophageal cancer	2.53e-05	0.000136	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—HMOX1—esophageal cancer	2.5e-05	0.000135	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.37e-05	0.000127	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.25e-05	0.000121	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP2A6—esophageal cancer	2.23e-05	0.00012	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CREBBP—esophageal cancer	2.12e-05	0.000114	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ENO1—esophageal cancer	2.11e-05	0.000114	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.11e-05	0.000114	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PSME1—esophageal cancer	2.08e-05	0.000112	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PSME2—esophageal cancer	2.08e-05	0.000112	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—NOS3—esophageal cancer	1.9e-05	0.000102	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.79e-05	9.66e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTGS2—esophageal cancer	1.74e-05	9.36e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.69e-05	9.08e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CREBBP—esophageal cancer	1.6e-05	8.63e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.54e-05	8.29e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.48e-05	7.95e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—EP300—esophageal cancer	1.45e-05	7.79e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—NOS3—esophageal cancer	1.44e-05	7.73e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTGS2—esophageal cancer	1.31e-05	7.07e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—EP300—esophageal cancer	1.09e-05	5.88e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CA—esophageal cancer	1.07e-05	5.76e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CREBBP—esophageal cancer	9.88e-06	5.32e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—NOS3—esophageal cancer	8.84e-06	4.76e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTGS2—esophageal cancer	8.09e-06	4.35e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CA—esophageal cancer	8.08e-06	4.35e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—EP300—esophageal cancer	6.73e-06	3.62e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CA—esophageal cancer	4.98e-06	2.68e-05	CbGpPWpGaD
